Sierra Oncology (Sierra Oncology) Shares Outstanding (Diluted Average) : 20.97 Mil (As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Sierra Oncology Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sierra Oncology's average diluted shares outstanding for the quarter that ended in Mar. 2022 was 20.97 Mil.

Sierra Oncology Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Sierra Oncology's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sierra Oncology Shares Outstanding (Diluted Average) Chart

Sierra Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Shares Outstanding (Diluted Average)

Get a 7-Day Free Trial

1.25

1.77

2.91

10.51

13.25

Sierra Oncology Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Shares Outstanding (Diluted Average)	Get a 7-Day Free Trial															11.67	12.35	13.67	15.30	20.97

Sierra Oncology Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

Sierra Oncology (NAS:SRRA) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Sierra Oncology Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Sierra Oncology's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sierra Oncology (Sierra Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sierra Oncology Inc (NAS:SRRA) » Definitions » Shares Outstanding (Diluted Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1820 Gateway Drive, Suite 110, San Mateo, USA, 94404

Website

https://www.sierraoncology.com

Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.

Executives

Vivo Opportunity Fund Holdings, L.p.	director, 10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
William D. Turner	officer: Chief Reg & Tech Ops Officer	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Mary Christina Thomson	officer: General Counsel	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Joshua Richardson	director, 10 percent owner	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Gaurav Aggarwal	director, 10 percent owner	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Andrew Sinclair	director	C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Georgia Erbez	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459